Recent developments in the treatment of advanced bladder cancer

James Luke Godwin, Jean Hoffman-Censits, Elizabeth Plimack

Research output: Contribution to journalReview articlepeer-review


Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Issue number3
StatePublished - Mar 2018
Externally publishedYes


  • Bladder cancer
  • Checkpoint inhibitors
  • Chemotherapy
  • Clinical trials
  • Immunotherapy
  • Platinum ineligible
  • Targeted therapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Recent developments in the treatment of advanced bladder cancer'. Together they form a unique fingerprint.

Cite this